These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 25692924

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.
    Toth PP.
    Vasc Health Risk Manag; 2016; 12():171-83. PubMed ID: 27226718
    [Abstract] [Full Text] [Related]

  • 3. Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
    Taskinen MR, Borén J.
    Curr Atheroscler Rep; 2016 Oct; 18(10):59. PubMed ID: 27613744
    [Abstract] [Full Text] [Related]

  • 4. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
    Taskinen MR, Packard CJ, Borén J.
    Curr Atheroscler Rep; 2019 May 20; 21(8):27. PubMed ID: 31111320
    [Abstract] [Full Text] [Related]

  • 5. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM.
    Circ Res; 2013 May 24; 112(11):1479-90. PubMed ID: 23542898
    [Abstract] [Full Text] [Related]

  • 6. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
    van Capelleveen JC, Bernelot Moens SJ, Yang X, Kastelein JJP, Wareham NJ, Zwinderman AH, Stroes ESG, Witztum JL, Hovingh GK, Khaw KT, Boekholdt SM, Tsimikas S.
    Arterioscler Thromb Vasc Biol; 2017 Jun 24; 37(6):1206-1212. PubMed ID: 28473441
    [Abstract] [Full Text] [Related]

  • 7. New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
    Olkkonen VM, Sinisalo J, Jauhiainen M.
    Atherosclerosis; 2018 May 24; 272():27-32. PubMed ID: 29544086
    [Abstract] [Full Text] [Related]

  • 8. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
    Chan DC, Chen MM, Ooi EM, Watts GF.
    Int J Clin Pract; 2008 May 24; 62(5):799-809. PubMed ID: 18201179
    [Abstract] [Full Text] [Related]

  • 9. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J, Gouni-Berthold I.
    Curr Med Chem; 2018 May 24; 25(13):1567-1576. PubMed ID: 28595549
    [Abstract] [Full Text] [Related]

  • 10. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
    Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP.
    Arterioscler Thromb Vasc Biol; 2015 Aug 24; 35(8):1880-8. PubMed ID: 26069232
    [Abstract] [Full Text] [Related]

  • 11. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
    Dallinga-Thie GM, Kroon J, Borén J, Chapman MJ.
    Curr Cardiol Rep; 2016 Jul 24; 18(7):67. PubMed ID: 27216847
    [Abstract] [Full Text] [Related]

  • 12. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Chan DC, Watts GF.
    Curr Opin Lipidol; 2024 Jun 01; 35(3):101-109. PubMed ID: 38372218
    [Abstract] [Full Text] [Related]

  • 13. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I.
    Atheroscler Suppl; 2017 Nov 01; 30():19-27. PubMed ID: 29096837
    [Abstract] [Full Text] [Related]

  • 14. The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis.
    Wyler von Ballmoos MC, Haring B, Sacks FM.
    J Clin Lipidol; 2015 Nov 01; 9(4):498-510. PubMed ID: 26228667
    [Abstract] [Full Text] [Related]

  • 15. Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.
    Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, Oberhollenzer F, Egger G, Witztum JL, Alexander VJ, Willeit J, Kiechl S, Mayr M.
    J Am Coll Cardiol; 2017 Feb 21; 69(7):789-800. PubMed ID: 28209220
    [Abstract] [Full Text] [Related]

  • 16. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H, Diabetes Atorvastatin Lipid intervention (DALI) Study Group.
    Diabetes Care; 2004 Jun 21; 27(6):1358-64. PubMed ID: 15161788
    [Abstract] [Full Text] [Related]

  • 17. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
    Wolska A, Lo L, Sviridov DO, Pourmousa M, Pryor M, Ghosh SS, Kakkar R, Davidson M, Wilson S, Pastor RW, Goldberg IJ, Basu D, Drake SK, Cougnoux A, Wu MJ, Neher SB, Freeman LA, Tang J, Amar M, Devalaraja M, Remaley AT.
    Sci Transl Med; 2020 Jan 29; 12(528):. PubMed ID: 31996466
    [Abstract] [Full Text] [Related]

  • 18. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
    Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD.
    J Clin Invest; 2016 Aug 01; 126(8):2855-66. PubMed ID: 27400128
    [Abstract] [Full Text] [Related]

  • 19. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
    Reeskamp LF, Tromp TR, Stroes ESG.
    Curr Opin Lipidol; 2020 Jun 01; 31(3):140-146. PubMed ID: 32324598
    [Abstract] [Full Text] [Related]

  • 20. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
    Onat A, Hergenç G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G.
    Atherosclerosis; 2003 May 01; 168(1):81-9. PubMed ID: 12732390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.